
## **Richard Kones**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/221286/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Design, Development and Therapy, 2011, 5, 325.	4.3	201
2	Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease & amp;ndash; a perspective. Drug Design, Development and Therapy, 2010, 4, 383.	4.3	91
3	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vascular Health and Risk Management, 2013. 9. 617.	2.3	71
4	Recent advances in the management of chronic stable angina I: Approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities. Vascular Health and Risk Management, 2010, 6, 635.	2.3	43
5	ls prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention. Therapeutic Advances in Cardiovascular Disease, 2011, 5, 61-81.	2.1	37
6	Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies. Clinical Therapeutics, 2019, 41, 1780-1797.	2.5	35
7	Cardiometabolic diseases of civilization: history and maturation of an evolving global threat. An update and call to action. Annals of Medicine, 2017, 49, 260-274.	3.8	29
8	n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: Principles, Practices, Pitfalls, and Promises - A Contemporary Review. Medical Principles and Practice, 2017, 26, 497-508.	2.4	25
9	Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional Therapies. Drugs, 2015, 75, 1187-1199.	10.9	24
10	Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate–high cardiovascular risk. Journal of Nutritional Biochemistry, 2014, 25, 642-646.	4.2	19
11	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs. Drugs, 2015, 75, 1201-1228.	10.9	18
12	Confronting the most challenging risk factor: non-adherence. Lancet, The, 2019, 393, 105-106.	13.7	17
13	Exclusion of â€~nonRCT evidence' in guidelines for chronic diseases – is it always appropriate? The Look AHEAD study. Current Medical Research and Opinion, 2014, 30, 2009-2019.	1.9	12
14	Cultural primer for cardiometabolic health: health disparities, structural factors, community, pathways to improvement, and clinical applications. Postgraduate Medicine, 2018, 130, 200-221.	2.0	7
15	Barriers to Global Action Plan for the Prevention and Control of Noncommunicable Diseases: Proposal Modifications to the Voluntary Targets. Journal of Preventive Medicine, 2018, 03, .	0.4	7
16	Cardiovascular Prevention: Components, Levels, Early Origins, and Metrics. Hospital Practice (1995), 2014, 42, 84-95.	1.0	5
17	Trends in Guideline-Driven Revascularization in Diabetic Patients with Multivessel Coronary Heart Disease. Journal of Cardiovascular Development and Disease, 2019, 6, 41.	1.6	4
18	Cardiac rehabilitation underutilization: Missed opportunities in comprehensive cardiac care. International Journal of Cardiology, 2019, 292, 39-40.	1.7	3

#	Article	IF	CITATIONS
19	Inflammation, C-reactive protein and cardiometabolic risk: how compelling is the potential therapeutic role of n-3 PUFAs in cardiovascular disease?. Clinical Lipidology, 2011, 6, 627-630.	0.4	1
20	Dyslipidemia, Risk Factors, and the Prevention of Cardiovascular Disease in Women. Journal of Women's Health, 2013, 22, 402-403.	3.3	1
21	A General Pathway Model for Improving Health Disparities: Lessons from Community and Cultural Involvement in Improving Cervical Cancer Screening in Vietnamese Women. Journal of Clinical Medicine, 2019, 8, 154.	2.4	1